Working… Menu

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00004895
Recruitment Status : Completed
First Posted : May 9, 2003
Last Update Posted : June 6, 2012
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Northwestern University

Brief Summary:

RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably.

PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that cannot be removed by surgery.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Constipation, Impaction, and Bowel Obstruction Extrahepatic Bile Duct Cancer Gastric Cancer Gastrointestinal Stromal Tumor Nausea and Vomiting Ovarian Cancer Pancreatic Cancer Peritoneal Cavity Cancer Small Intestine Cancer Drug: octreotide acetate Phase 2

Detailed Description:


  • Determine the effectiveness of octreotide in the palliation of bowel obstruction secondary to cancer.
  • Characterize the dose and tolerability of octreotide in this patient population.

OUTLINE: Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5.

Patients who respond well to study may continue octreotide for palliative effects.

PROJECTED ACCRUAL: A total of 9-25 patients will be accrued for this study over 9 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Supportive Care
Official Title: Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study
Study Start Date : October 1999
Actual Primary Completion Date : October 2002
Actual Study Completion Date : October 2002

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Inoperable bowel obstruction secondary to cancer OR
  • Metastatic or primary abdominal cancer
  • Patient presents with vomiting
  • Percutaneous gastrostomy tube allowed



  • Over 18

Performance status:

  • ECOG 0-4

Life expectancy:

  • Not specified


  • Not specified


  • Not specified


  • Not specified


  • No documented hypersensitivity to octreotide
  • Not pregnant or nursing


Biologic therapy:

  • Not specified


  • Prior chemotherapy allowed

Endocrine therapy:

  • Concurrent steroids allowed


  • Prior radiotherapy allowed


  • Not specified

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00004895

Layout table for location information
United States, Illinois
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States, 60611-3013
Sponsors and Collaborators
Northwestern University
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: J. Cameron Muir, MD Robert H. Lurie Cancer Center

Layout table for additonal information
Responsible Party: Northwestern University Identifier: NCT00004895     History of Changes
Other Study ID Numbers: NU 97X1
First Posted: May 9, 2003    Key Record Dates
Last Update Posted: June 6, 2012
Last Verified: May 2012
Keywords provided by Northwestern University:
stage I colon cancer
stage II colon cancer
stage III colon cancer
stage IV colon cancer
stage I gastric cancer
stage II gastric cancer
stage III gastric cancer
stage IV gastric cancer
recurrent gastric cancer
stage I pancreatic cancer
stage II pancreatic cancer
stage III pancreatic cancer
stage IV pancreatic cancer
recurrent pancreatic cancer
stage I rectal cancer
stage II rectal cancer
stage III rectal cancer
stage IV rectal cancer
recurrent colon cancer
recurrent rectal cancer
stage I ovarian epithelial cancer
stage II ovarian epithelial cancer
stage III ovarian epithelial cancer
stage IV ovarian epithelial cancer
recurrent ovarian epithelial cancer
small intestine adenocarcinoma
small intestine lymphoma
small intestine leiomyosarcoma
localized extrahepatic bile duct cancer
unresectable extrahepatic bile duct cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Stomach Neoplasms
Gastrointestinal Stromal Tumors
Bile Duct Neoplasms
Intestinal Neoplasms
Intestinal Obstruction
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Endocrine Gland Neoplasms
Pancreatic Diseases
Endocrine System Diseases
Stomach Diseases
Signs and Symptoms, Digestive
Signs and Symptoms
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Biliary Tract Neoplasms
Bile Duct Diseases
Biliary Tract Diseases